Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for c…
The bill amends Medicare (Title XVIII) to cover Alpha-1 Antitrypsin Deficiency augmentation therapy furnished in a patient’s home by qualified home infusion therapy suppliers.
It creates Medicare Part B payment authority for intravenous administration kits and up to two hours of nursing services per infusion, establishes direct payment to suppliers, and excludes those items from home health coverage.
The bill defines eligible patients and providers, sets an 80 percent payment rule for these kits and services, and applies to items and services furnished on or after January 1, 2027.
Technically straightforward, patient-advocate friendly change with modest cost, but requires CMS implementation and possible Senate floor compromises.
Relative to its intended legislative type, this bill is a narrowly scoped substantive change to Medicare that reasonably defines a new Part B benefit for Alpha-1 augmentation therapy furnished at home and establishes payment authority and basic integration with existing statutory provisions, but it has moderate shortcomings in precision and in providing fiscal, procedural, and accountability detail.
Support for home access versus concern about expanding Medicare spending
Support for home access versus concern about expanding Medicare spending
Likely strongly supportive.
The bill expands access to a clinically necessary rare-disease therapy in the home, reducing travel and facility reliance.
Concerns would center on the exclusion of Medicare Advantage enrollees and whether payment rates ensure provider participation.
Generally supportive but cautious.
The bill targets a narrow clinical need and may improve access and convenience, but it raises questions about cost, implementation details, and benefit fragmentation between traditional Medicare and Medicare Advantage.
Skeptical.
While home infusion can benefit patients, this bill expands Medicare benefit obligations and spending for a specific therapy.
Conservatives would question federal cost increases and prefer private/MA delivery or targeted, cost-neutral pilots.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Technically straightforward, patient-advocate friendly change with modest cost, but requires CMS implementation and possible Senate floor compromises.
The bill has not accumulated any surfaced votes yet.
Support for home access versus concern about expanding Medicare spending
Technically straightforward, patient-advocate friendly change with modest cost, but requires CMS implementation and possible Senate floor c…
Relative to its intended legislative type, this bill is a narrowly scoped substantive change to Medicare that reasonably defines a new Part B benefit for Alpha-1 augmentation therapy furnished at home and establishes pa…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.